Elsevier

Cancer Treatment Reviews

Volume 39, Issue 5, August 2013, Pages 534-540
Cancer Treatment Reviews

Laboratory-Clinic Interface
The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer

https://doi.org/10.1016/j.ctrv.2012.08.003Get rights and content

Summary

Since the initial work, a decade ago that the combination of C-reactive protein and albumin, the Glasgow Prognostic Score (GPS), had independent prognostic value in patients with cancer, there have been more than 60 studies (>30,000 patients) that have examined and validated the use of the GPS or the modified GPS (mGPS) in a variety of cancer scenarios. The present review provides a concise overview of these studies and comments on the current and future clinical utility of this simple objective systemic inflammation-based score. The GPS/mGPS had independent prognostic value in (a) unselected cohorts (4 studies, >19,400 patients) (b) operable disease (28 studies, >8,000 patients) (c) chemo/radiotherapy (11 studies, >1500 patients) (d) inoperable disease (11 studies, >2,000 patients). Association studies (15 studies, >2,000 patients) pointed to an increased GPS/mGPS being associated with increased weight and muscle loss, poor performance status, increased comorbidity, increased pro-inflammatory and angiogenic cytokines and complications on treatment. These studies have originated from 13 different countries, in particular the UK and Japan. A chronic systemic inflammatory response, as evidenced by the GPS/mGPS, is clearly implicated in the prognosis of patients with cancer in a variety of clinical scenarios. The GPS/mGPS is the most extensively validated of the systemic inflammation-based prognostic scores and therefore may be used in the routine clinical assessment of patients with cancer. It not only identifies patients at risk but also provides a well defined therapeutic target for future clinical trials. It remains to be determined whether the GPS has prognostic value in other disease states.

Introduction

Cancer remains the leading cause of death worldwide in individuals aged 35–64 years and globally accounts for at least 500,000 deaths each year. In the UK approximately one in three develops cancer and one in four dies of cancer. Despite this relatively poor outcome for most common cancers, much high profile research is carried out with a view to cure whereas the reality for most patients with cancer is disease progression and death.

Therefore, against this background, predicting the likely outcome of the patient with cancer is of considerable importance since even without improvements in treatment, if patients are given the appropriate treatment, then outcomes will improve for all patients. Unfortunately, without objective measures of likely outcome, the allocation of treatment will continue to be suboptimal. For example, Temel and coworkers1 recently reported that, in patients with metastatic lung cancer randomised to palliative care vs standard care, palliative care was associated with better quality of life and increased survival.

Currently, the cornerstone of cancer prognosis is accurate staging of the tumour and establishing whether there has been tumour spread. However, there is increasing recognition that patient related factors, in particular nutritional and functional decline, are associated with poorer outcome independent of tumour stage. The most commonly used measures of this decline, weight loss and performance status, are recognised to be subjective and therefore their reliability in predicting outcome is compromised. Moreover, they do not provide objective therapeutic targets.

There is now good consistent evidence that the presence of a systemic inflammatory response is a major factor underlying such patient decline.[2], [3], [4], [5] Since the initial studies of using C-reactive protein, as a sensitive measure of the systemic inflammatory response, reported independent prognostic value in operable colorectal cancer[6], [7] there have been a plethora of studies reporting the prognostic value of C-reactive protein and other markers of the systemic inflammatory response in a wide variety of operable8 and inoperable9 cancers.

In this early work it was noted as circulating C-reactive protein concentrations increased albumin concentrations fell and this relationship was similar across different tumour types.10 Also, given that albumin concentrations reflected both systemic inflammation and the amount of lean tissue,11 it was of interest to examine the prognostic value of the combination of an elevated C-reactive protein concentration (>10 mg/l) and hypoalbuminaemia (<35 g/l). In the first report by Forrest and coworkers in Glasgow, this objective combination compared favourably with the clinical standard combination of stage and performance status.12 The resultant prognostic score (0, 1, 2) was defined as follows; patients with both an elevated C-reactive protein (>10 mg/l) and hypoalbuminaemia (<35 g/l) were allocated a score of 2. Patients in whom only one of these biochemical abnormalities was present were allocated a score of 1. Patients in whom neither of these abnormalities was present were allocated a score of 0. However, the score of 1 was most commonly due to an elevated C-reactive protein emphasising the inflammatory basis of the GPS (Table 1,12).

This systemic inflammation based prognostic score was subsequently termed the Glasgow Prognostic Score (GPS,13). On further investigation the GPS was modified, termed the mGPS, to reflect the observation that hypoalbuminaemia without an elevated C-reactive protein concentration was rare and that hypoalbuminaemia on its own was not associated with poor survival (Table 1,14). The GPS/mGPS being simple to measure, routinely available and well standardised world-wide has subsequently been the subject of prognostic studies in wide variety of operable and inoperable cancers. Since the initial work, a decade ago, there have been more than 60 studies (>30,000 cancer patients) that have examined and validated the use of the GPS/mGPS in a variety of clinical scenarios. The present review provides a concise overview of these studies and comments on the current and future clinical utility of this simple objective systemic inflammation-based score.

Section snippets

Methods

This systematic review of published literature was undertaken according to a pre-defined protocol. The primary outcome of interest was the relationship between the GPS/mGPS and cancer outcome (overall survival, cancer specific survival, disease recurrence or response to treatment). The secondary outcomes of interest were the associations between the GPS/mGPS and other clinical, pathological or inflammatory characteristics.

A literature search, using appropriate free text and medical subject

Studies of the prognostic value of the GPS/mGPS, in an unselected cohort of patients with cancer

Four studies, comprising data on 19,481 patients, reported prognostic value of the GPS/mGPS in unselected cohorts of patients with cancer (Table 2,[15], [16], [17], [18]). All studies used the mGPS and reported prognostic value independent of tumour site (breast, bladder, gynaecological, prostate, gastro-oesophageal, haematological, renal, colorectal, head and neck, hepatopancreaticobiliary and pulmonary) and were from the Glasgow group. Two studies compared the prognostic value of the GPS/mGPS

Studies of the prognostic value of the GPS/mGPS in patients with operable cancer

Twenty-eight studies, comprising data on 8,333 patients, reported prognostic value of the GPS/mGPS in patients with operable cancer (Table 3,[14], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46]). Fourteen studies were in colorectal (including liver metastases) cancer and the GPS/mGPS was reported to have prognostic value independent of tumour stage and pathological features,

Studies of the prognostic value of the GPS/mGPS, in cancer patients receiving chemo/radiotherapy

Eleven studies, comprising data on 1,504 patients, reported prognostic value of the GPS/mGPS in cancer patients receiving chemo/radiotherapy (Table 4,[13], [47], [48], [49], [50], [51], [52], [53], [54], [55], [56]). Four studies were in gastro-oesophageal cancer and the GPS/mGPS was reported to have prognostic value independent of tumour stage and performance status. These studies were from groups in the UK (1 study), Japan (1 study), Taiwan (1 study) and South Korea (1 study). Over these four

Studies of the prognostic value of the GPS/mGPS, in patients with inoperable cancer

Eleven studies, comprising data on 2,119 patients, reported prognostic value of the GPS/mGPS in patients with inoperable cancer (Table 5,[57], [58], [59], [60], [61], [62], [63], [64], [65], [66], [67]). Three studies were in lung cancer and the GPS/mGPS was reported to have prognostic value independent of tumour stage, performance status and treatment and other measures of the systemic inflammatory response. These 3 studies were from groups in the UK. Over these three studies the weighted

Studies of the associations with the GPS/mGPS in patients with cancer

Fifteen studies, comprising data on 2,215 patients, reported associations between the GPS/mGPS and weight and muscle loss, nutritional status, performance status, biochemical and cytokine disturbances (Table 6,[68], [69], [70], [71], [72], [73], [74], [75], [76], [77], [78], [79], [80], [81], [82]). This was particularly evident in gastro-oesophageal (5 studies), colorectal (5 studies) and lung (2 studies) cancer. There were also single studies in hepatocellular cancer, pancreas and ear nose

Discussion

From the present review and given that the HR was similar across different tumours, countries and clinical scenarios it can be concluded that GPS/mGPS is a reliable independent prognostic factor in patients with cancer. Its use has been reported in (a) unselected cohorts (4 studies, >19,400 patients) (b) operable disease (28 studies, >8,000 patients) (c) chemo/radiotherapy (11 studies, >1500 patients) (d) inoperable disease 11 studies, >2,000 patients). Also, association studies (15 studies,

Acknowledgements

The author gratefully acknowledges the support and advice of clinical and scientific colleagues at Glasgow Royal Infirmary, in particular Professors of Surgery Clem Imrie and Paul Horgan, and funding from Glasgow Royal Infirmary Endowment Funds, the Chief Scientist Office and Cancer Research UK.

References (85)

  • P. Glen et al.

    Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer

    Pancreatology

    (2006)
  • R. Sharma et al.

    Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer

    Eur J Cancer

    (2008)
  • D.J. Pinato et al.

    Inflammation-based prognostic indices in malignant pleural mesothelioma

    J Thorac Oncol

    (2012)
  • E.Y. Leung et al.

    Clinical utility of the pretreatment Glasgow Prognostic Score in patients with advanced inoperable non-small cell lung cancer

    J Thorac Oncol

    (2012)
  • C.L. Meek et al.

    The relationship between the insulin-like growth factor-1 axis, weight loss, an inflammation-based score and survival in patients with inoperable non-small cell lung cancer

    Clin Nutr

    (2010)
  • D. Diakowska et al.

    Circulating leptin and inflammatory response in esophageal cancer, esophageal cancer-related cachexia-anorexia syndrome (CAS) and non-malignant CAS of the alimentary tract

    Cytokine

    (2010)
  • J. Blomberg et al.

    Albumin and C-reactive protein levels predict short-term mortality after percutaneous endoscopic gastrostomy in a prospective cohort study

    Gastrointest Endosc

    (2011)
  • A. Macciò et al.

    A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life

    Gynecol Oncol

    (2012)
  • J.S. Temel et al.

    Early palliative care for patients with metastatic non-small-cell lung cancer

    N Engl J Med

    (2010)
  • D.C. McMillan

    An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer

    Proc Nutr Soc

    (2008)
  • D.C. McMillan

    Systemic inflammation, nutritional status and survival in patients with cancer

    Curr Opin Clin Nutr Metab Care

    (2009)
  • N. Macdonald

    Chronic inflammatory states: their relationship to cancer prognosis and symptoms

    J R Coll Physicians Edinb

    (2011)
  • D.C. McMillan et al.

    Systemic inflammatory response predicts survival following curative resection of colorectal cancer

    Br J Surg

    (2003)
  • C.S. Roxburgh et al.

    Role of systemic inflammatory response in predicting survival in patients with primary operable cancer

    Future Oncol

    (2010)
  • S.J. Clarke et al.

    Use of inflammatory markers to guide cancer treatment

    Clin Pharmacol Ther

    (2011)
  • D.C. McMillan et al.

    Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer

    Nutr Cancer

    (2001)
  • D.C. McMillan et al.

    Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss

    Nutr Cancer

    (2001)
  • L.M. Forrest et al.

    Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer

    Br J Cancer

    (2003)
  • L.M. Forrest et al.

    Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer

    Br J Cancer

    (2004)
  • D.C. McMillan et al.

    Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer

    Int J Colorectal Dis

    (2007)
  • M.J. Proctor et al.

    An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study

    Br J Cancer

    (2011)
  • K. Shafique et al.

    Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study

    Prostate Cancer Prostatic Dis

    (2012)
  • E.F. Leitch et al.

    Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer

    Br J Cancer

    (2007)
  • M. Ishizuka et al.

    Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer

    Ann Surg

    (2007)
  • C.S. Roxburgh et al.

    Comparison of tumour-based (Petersen Index) and inflammation-based (Glasgow Prognostic Score) scoring systems in patients undergoing curative resection for colon cancer

    Br J Cancer

    (2009)
  • L.H. Moyes et al.

    Preoperative systemic inflammation predicts postoperative infectious complications in patients undergoing curative resection for colorectal cancer

    Br J Cancer

    (2009)
  • C.S. Roxburgh et al.

    Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer

    Ann Surg

    (2009)
  • M. Ishizuka et al.

    Systemic inflammatory response predicts postoperative outcome in patients with liver metastases from colorectal cancer

    J Surg Oncol

    (2009)
  • M. Ishizuka et al.

    Systemic inflammatory response associated with distant metastasis of T1 or T2 colorectal cancer

    Dig Dis Sci

    (2010)
  • T. Kobayashi et al.

    Inflammation-based prognostic score and number of lymph node metastases are independent prognostic factors in esophageal squamous cell carcinoma

    Dig Surg

    (2010)
  • S. Polterauer et al.

    The inflammation-based Glasgow Prognostic Score predicts survival in patients with cervical cancer

    Int J Gynecol Cancer

    (2010)
  • T. Kobayashi et al.

    Elevated C-reactive protein and hypoalbuminemia measured before resection of colorectal liver metastases predict postoperative survival

    Dig Surg

    (2010)
  • Cited by (0)

    View full text